City Holding Co. increased its position in Merck & Company, Inc. (NYSE:MRK) by 2.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,953 shares of the company’s stock after acquiring an additional 186 shares during the quarter. City Holding Co.’s holdings in Merck & were worth $510,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. HM Capital Management LLC increased its holdings in Merck & by 0.4% in the 1st quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock worth $236,000 after acquiring an additional 15 shares in the last quarter. Bath Savings Trust Co increased its holdings in Merck & by 0.5% in the 2nd quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock worth $348,000 after acquiring an additional 28 shares in the last quarter. Camelot Portfolios LLC increased its holdings in Merck & by 0.4% in the 1st quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock worth $494,000 after acquiring an additional 33 shares in the last quarter. Stillwater Investment Management LLC increased its holdings in Merck & by 0.8% in the 2nd quarter. Stillwater Investment Management LLC now owns 4,621 shares of the company’s stock worth $296,000 after acquiring an additional 38 shares in the last quarter. Finally, Alexandria Capital LLC increased its holdings in Merck & by 0.6% in the 1st quarter. Alexandria Capital LLC now owns 10,106 shares of the company’s stock worth $642,000 after acquiring an additional 58 shares in the last quarter. 72.91% of the stock is owned by institutional investors.

Several equities research analysts recently issued reports on the stock. BidaskClub lowered shares of Merck & from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. BMO Capital Markets reaffirmed an “outperform” rating and set a $73.00 price objective (down from $74.00) on shares of Merck & in a report on Monday, July 24th. Citigroup Inc. set a $65.00 price objective on shares of Merck & and gave the company a “hold” rating in a report on Wednesday, July 5th. Zacks Investment Research lowered shares of Merck & from a “buy” rating to a “hold” rating in a report on Thursday, May 25th. Finally, Jefferies Group LLC reaffirmed a “sell” rating and set a $51.00 price objective on shares of Merck & in a report on Wednesday, May 24th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $70.00.

WARNING: This article was first posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/09/21/city-holding-co-has-510000-position-in-merck-company-inc-mrk.html.

Merck & Company, Inc. (NYSE:MRK) traded up 0.15% on Thursday, hitting $65.89. The stock had a trading volume of 2,093,028 shares. The company has a market cap of $179.71 billion, a PE ratio of 35.67 and a beta of 0.81. The company has a 50-day moving average of $63.52 and a 200 day moving average of $63.68. Merck & Company, Inc. has a 12 month low of $58.29 and a 12 month high of $66.80.

Merck & (NYSE:MRK) last issued its quarterly earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The firm had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. During the same period in the previous year, the business earned $0.93 earnings per share. The firm’s revenue for the quarter was up .9% on a year-over-year basis. On average, analysts predict that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Investors of record on Friday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 2.86%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s payout ratio is 76.11%.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.